Paclitaxel and carboplatin in patients with metastatic urothelial cancer: results of a phase 11 trial
1998

Paclitaxel and Carboplatin for Metastatic Urothelial Cancer

Sample size: 20 publication Evidence: moderate

Author Information

Author(s): CC Zielinski, B Schnack, M Grbovic, T Brodowicz, C Wiltschke, G Steger, H PflOger, M Marberger

Primary Institution: University Hospital, Vienna, Austria

Hypothesis

The study aims to assess the efficacy and toxicity of a combination of paclitaxel and carboplatin as first-line chemotherapy in patients with metastatic transitional cell carcinoma of the urothelium.

Conclusion

The combination of paclitaxel and carboplatin is an effective and well-tolerated first-line treatment for metastatic urothelial cancer.

Supporting Evidence

  • 65% of patients achieved remissions, with 40% achieving complete remission.
  • 80% of patients were alive after a mean observation period of 11.4 months.
  • The mean duration of responses was 8.5 months.

Takeaway

This study tested a new medicine for patients with a type of bladder cancer, and it helped many of them feel better without making them too sick.

Methodology

Patients received paclitaxel and carboplatin every 21 days, and their responses were monitored over a mean observation period of 11.4 months.

Limitations

The study had a small sample size and was limited to patients with specific inclusion criteria.

Participant Demographics

The study included 20 patients (12 women, 8 men) with a mean age of 67 years, ranging from 50 to 79 years.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication